XW023X7
XW023X7 — Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
Billable / specific codeICD-10-PCS
CMS abbreviated title: Introduce Tixagev/Cilgavim in Muscle, Perc, New Tech 7
How XW023X7 is built
Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.
- XSectionNew Technology — What family of procedure this is
- WBody systemWhich system it acts on
- 0Root operationThe objective — the verb of the procedure
- 2Body partThe specific site
- 3ApproachHow the site was reached
- XDeviceWhat was left in place, if anything
- 7QualifierA further distinction where one applies
Codes near XW023X7
In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.
- XW013W7Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW01X27Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
- XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
- XW023S6Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
- XW023T6Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
- XW023U6Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
- XW023V7Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
- XW023W7Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
- XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
- XW023Y7Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
- XW03308Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW0333AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW0334AIntroduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW03357Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW03358Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW0335AIntroduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW03367Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7